PubMed Health⌕ Search

Biomedical subjects

L Bradford

Publications and source records attributed to L Bradford.

11 recordsLinked to original sources
PubMed1999

Developmental intervention for preterm infants diagnosed with periventricular leukomalacia.

Preterm infants with periventricular leukomalacia (PVL) were evaluated to determine whether multi-sensory stimulation is safe and to assess whether it improved neurobehavior and neurodevelopment. Thirty preterm infants with documented PVL were randomly assigned to control (n= 15) or experimental (Group E) (n= 15) groups at 33 weeks post-conceptional age. Group E infants received 15 minutes of auditory, tactile, visual, and vestibular (ATVV) intervention twice a day, five days a week, for four weeks during hospitalization. Repeated measures ANOVA demonstrated that Group E infants experienced significant increases in heart and respiratory rate and a 0.72% drop in hemoglobin saturation, coinciding with a significant behavioral state shift from sleep to alertness during intervention. No differences were identified in neurobehavioral function and neurodevelopment, indicating that Group E suffered no injury. Group E had an average hospital stay nine days shorter than that of controls, with the associated cost savings of $213,840. The earlier hospital discharge indicates that ATVV intervention promotes alertness without compromising physiologic status in vulnerable infants.

Analysis of Variance↗
PubMed1997

Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.

Screening of a compound library for inhibitors of the fibroblast growth factor (FGFr) and platelet-derived growth factor (PDGFr) receptor tyrosine kinases led to the development of a novel series of ATP competitive pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. The initial lead, 1-[2-amino-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3- tert-butylurea (4b, PD-089828), was found to be a broadly active tyrosine kinase inhibitor. Compound 4b inhibited the PDGFr, FGFr, EGFr, and c-src tyrosine kinases with IC50 values of 1.11, 0.13, 0.45, and 0.22 microM, respectively. Subsequent SAR studies led to the synthesis of new analogs with improved potency, solubility, and bioavailability relative to the initial lead. For example, the introduction of a [4-(diethylamino)butyl]amino side chain into the 2-position of 4b afforded compound 6c with enhanced potency and bioavailability. Compound 6c inhibited PDGF-stimulated vascular smooth muscle cell proliferation with an IC50 of 0.3 microM. Furthermore, replacement of the 6-(2,6-dichlorophenyl) moiety of 4b with a 6-(3',5'-dimethoxyphenyl) functionality produced a highly selective FGFr tyrosine kinase inhibitor 4e. Compound 4e inhibited the FGFr tyrosine kinase with an IC50 of 0.060 microM, whereas IC50s for the inhibition of the PDGFr, FGFr, EGFr, c-src, and InsR tyrosine kinases for this compound (4e) were all greater than 50 microM.

Animals↗
PubMed1996

Liquid chromatographic assay for a butenolide endothelin antagonist (PD 156707) in plasma.

A sensitive and selective liquid chromatographic assay for determining the non-peptide endothelin A receptor antagonist PD 156707 (I) in rat plasma has been developed and validated. The analyte was isolated from matrix by solid-phase extraction. Liquid chromatographic separation was achieved isocratically on a 3.2 mm I.D., ODS column with a mobile phase of acetonitrile-ammonium phosphate (50 mM, pH 3.5) (44:56, v/v). Column effluent was monitored fluorometrically. Peak-height ratios (analyte/IS) were proportional to I concentrations in rat plasma from 25 to 1000 ng/ml. Assay precision and accuracy for I, based on quality controls, was 9.5% relative standard deviation, with relative error of +/- 6.5%. The quantitation limit was 25 ng/ml for a 200-microliters sample aliquot.

Animals↗
PubMed1996

Pediatric soft-tissue sarcomas.

Pediatric soft-tissue sarcomas represent a relatively common problem in pediatric oncology. The evaluation of these lesions has contributed significantly to the understanding of the molecular basis of sarcomas, and the adjuvant treatment of these tumors has resulted in improved local control and significant improvements in long-term survival. The essence of successful treatment involves preoperative imaging, followed by needle biopsy, preoperative neoadjuvant chemotherapy, and well-documented surgical resection. Indications for radiation therapy and the adequacy of surgical margins remain areas of further investigation. The identification and treatment of well-defined histologic and molecular subtypes will allow further improvements in treatment decisions and clinical results.

Child↗
PubMed1996

Endothelin A receptor antagonism by PD 156707 does not reduce infarct size after coronary artery occlusion/reperfusion in pigs.

Episodes of myocardial ischemia are associated with increases in cardiac venous plasma endothelin (ET) concentrations, suggesting that ET may play a role in the development of myocardial infarction. The purpose of this study was to determine if selective blockade of ET(A) receptors by PD 156707 reduces infarct size caused by coronary artery occlusion and reperfusion in pentobarbital-anesthetized micropigs. A PD 156707 dose which selectively blocks the ET(A)-mediated vasopressor response, but not the ET(B)-mediated vasodepressor response to i.v. ET-1 challenges (0.3 nmol/kg), was established in dose ranging studies in anesthetized micropigs. In myocardial infarction studies, micropigs received either saline vehicle (n = 7) or PD 156707 (n = 8) at a loading dose of 10 mg/kg/1 hr, followed by a maintenance dose of 7 mg/kg/hr. Coinciding with the start of the maintenance dose, the left anterior descending coronary artery was occluded for 1 hr followed by 3 hr of reperfusion. PD 156707 caused a significant (29 mm Hg) decrease in arterial blood pressure before occlusion. PD 156707 had no effect on infarct size (61.1 +/- 5.6% of the region at risk in the PD 156707 treatment group vs. 70.1 +/- 3.9% in the control group). These results suggest that ET(A) receptor activation does not substantially contribute to coronary artery occlusion/reperfusion-induced myocardial infarction.

Animals↗
PubMed1993

Keratin synthesis in SV40-transformed human keratinocytes after transient supertransfection with Harvey murine sarcoma viral DNA.

A transformed cell line (HE-IS) was established by transient supertransfection of a SV40-transformed human epidermal cell culture (HE-SL) (R. T. Su and Y.-C. Chang, 1989, Exp. Cell Res. 180, 117-133) with a recombinant plasmid containing an entire Harvey murine sarcoma virus DNA. HE-IS cells showed morphological alterations and less stringent growth requirements in a defined medium. A variant line (HE-TC), selected later from the HE-IS cells after a prolonged maintenance in serum-containing Dulbecco's minimal essential medium (DMEM), was found to be able to grow in either defined or serum-containing medium. Neither HE-IS nor HE-TC cells were able to form colonies in soft agar or induce tumors in athymic mice when inoculated subcutaneously. When grown in defined medium, all transformed cells (HE-SL, HE-IS, HE-TC) revealed a similar keratin pattern as analyzed by two-dimensional gel electrophoresis. However, significant reduction of keratins (notably K5) was detected in HE-TC cells maintained in serum-containing DMEM. The keratin pattern appeared to be regulated by the growth environment. Because of their nontumorigenic characteristics and defined growth properties, these transformed keratinocytes are likely to provide a suitable model system for examining the regulation of cytoskeleton protein synthesis.

Cell Division↗
PubMed1987

Low-dose phenobarbitone as an indicator of compliance with drug therapy.

1 To assess the potential value of low-dose phenobarbitone (PB) as a marker of compliance we studied the relationship between plasma level of PB and dose (2-16 mg daily) following 3 or 4 weeks treatment in healthy volunteers (n = 26) and in-patient volunteers (n = 7). 2 Also, to simulate poor compliance, PB levels were measured in some volunteers following alternate-day (n = 6) or short-term (n = 5) treatment with similar doses. These levels, expressed as the level: dose ratios (LDRs), did not overlap with those obtained following 3 or 4 weeks of daily PB intake. 3 To evaluate the efficacy of this marker in patients taking other drugs we gave a group of out-patients (n = 24) compound tablets containing B vitamins and a small dose (16 mg) of PB; their compliance over 2-5 weeks was assessed both by measuring plasma levels of PB and residual tablet counting. 4 In the latter study, as well as providing absolute evidence of good compliance by many patients, the plasma levels of PB proved particularly valuable when non-compliant individuals 'forgot' to bring their residual tablets. 5 We suggest that phenobarbitone, in doses low enough to be non-sedative and non-enzyme inducing, is potentially useful as a pharmacological indicator of compliance with drug therapy.

Adult↗
PubMed1982

Legionellosis--the 1980 San Francisco outbreak.

During the first half of March 1980, an unseasonal outbreak of legionellosis, which involved at least 14 of approximately 1,000 workers, occurred in a 6-month-old office building in San Francisco. An epidemiologic investigation revealed that persons 50 yr of age and older were at increased risk of disease. The outbreak was temporally associated with operation of the building's air conditioning system. In addition, Legionella pneumophila Serogroups 1, 4, and 6 were identified in water samples taken from a rooftop air conditioning cooling tower located directly across the street from an area of recent excavation.

Adult↗